The 23 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 120.00, with a high estimate of 154.00 and a low estimate of 69.00. The median estimate represents a +58.92% increase from the last price of 75.51.
The current consensus among 27 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since January, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.68
Reporting Date Feb 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.